Beth C. Seidenberg - Feb 7, 2024 Form 3 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role: Director, 10%+ Owner
Signature: By: /s/ Ryan Jones, as Attorney-in-Fact
Stock symbol: KYTX
Transactions as of: Feb 7, 2024
Transactions value $: $0
Form type: 3
Date filed: 2/7/2024, 09:55 PM
Previous filing: Jul 20, 2023
Next filing: Feb 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	KYTX	Stock Option (Right to Buy)							Feb 7, 2024	Common Stock	33K	$4.83	Direct	F1
holding	KYTX	Series A-1 Redeemable Convertible Preferred Stock							Feb 7, 2024	Common Stock	967K		See footnote	F2, F3
holding	KYTX	Series A-2 Redeemable Convertible Preferred Stock							Feb 7, 2024	Common Stock	1.94M		See footnote	F2, F3
holding	KYTX	Series B Redeemable Convertible Preferred Stock							Feb 7, 2024	Common Stock	880K		See footnote	F2, F3
holding	KYTX	Series B Redeemable Convertible Preferred Stock							Feb 7, 2024	Common Stock	736K		See footnote	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2	The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock has no expiration date and is convertible into the Issuer's Common Stock on a 1-for-4.5511 basis at any time. The number of underlying shares of Common Stock reported in Column 3 reflects an automatic conversion of each outstanding share of Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock into shares of Common Stock at a ratio of 1-for-4.5511 to be effective immediately prior to the closing of the Issuer's initial public offering.
F3	Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any.
F4	Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any.

Remarks:

Exhibit 24 - Power of Attorney